New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export SCTX’s income statement to Excel — free account
Scribe Therapeutics Inc.
SCTXScribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.
12.07
1.15
−8.70%
After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.
Follow SCTX
Alert me
| Dec '25 | |
|---|---|
P/E ratio |
0.00 |
P/S ratio |
1.84 |
P/FCF ratio |
0.00 |
P/Operating CF |
(4.75) |
P/B ratio |
0.00 |
Price to Tangible BV |
0.00 |
EV/Sales |
0.36 |
EV/EBITDA |
0.00 |
EV/Operating CF |
0.00 |
EV/FCF |
0.00 |
Earnings Yield |
(60.70%) |
Free Cash Flow Yield |
0.00% |
Revenue per Share |
21.07 |
EV/EBIT |
0.00 |
Price to Operating Income |
0.00 |
| Other line items | |
Graham Net Nets |
(1.07) |
Graham Number |
0.00 |
Columns are period end dates · fundamentals updated Nov 18, 2026